Breaking News Instant updates and real-time market news.

ATNM

Actinium Pharmaceuticals

$0.46

0.0079 (1.75%)

, BDSI

BioDelivery Sciences

$3.92

0.04 (1.03%)

04:55
01/09/19
01/09
04:55
01/09/19
04:55

LifeSci Advisors to hold a conference

8th Annual LifeSci Advisors Corporate Access Event will be held in San Francisco on January 7-9.

ATNM

Actinium Pharmaceuticals

$0.46

0.0079 (1.75%)

BDSI

BioDelivery Sciences

$3.92

0.04 (1.03%)

CTSO

CytoSorbents

$8.25

-0.305 (-3.57%)

GNCA

Genocea

$0.57

0.0337 (6.25%)

MDWD

MediWound

$4.29

-0.01 (-0.23%)

PFNX

Pfenex

$4.24

0.21 (5.21%)

ONS

Oncobiologics

$0.00

(0.00%)

NSPR

InspireMD

$0.18

0.012 (7.14%)

PTN

Palatin

$0.72

-0.0358 (-4.72%)

PRTA

Prothena

$11.41

0.04 (0.35%)

DRRX

Durect

$0.56

0.0035 (0.63%)

TCON

TRACON Pharmaceuticals

$0.82

-0.0005 (-0.06%)

VBLT

VBL Therapeutics

$1.08

-0.02 (-1.82%)

VELO

VeloCom Inc.

$0.00

(0.00%)

ZGNX

Zogenix

$44.47

1.24 (2.87%)

FOMX

Foamix

$4.02

-0.04 (-0.99%)

LIFE

aTyr Pharma

$0.54

-0.0209 (-3.72%)

ENTX

Entera Bio

$3.12

(0.00%)

CBIO

Catalyst Biosciences

$9.48

-0.51 (-5.11%)

INSP

Inspire Medical

$46.24

0.65 (1.43%)

OCX

OncoCyte

$1.88

0.24 (14.63%)

  • 09

    Jan

  • 09

    Jan

  • 20

    Feb

ATNM Actinium Pharmaceuticals
$0.46

0.0079 (1.75%)

07/12/18
RILY
07/12/18
NO CHANGE
Target $3
RILY
Buy
Actinium price target raised to $3 from $2.75 at B. Riley FBR
B. Riley FBR analyst George Zavoico raised his price target for Actinium Pharmaceuticals to $3.00 from $2.75 and keeps a Buy rating on the shares. The company's new Phase I trial for Actimab-A MRDexpands its footprint in acute myeloid leukemia, Zavoico tells investors in a research note.
BDSI BioDelivery Sciences
$3.92

0.04 (1.03%)

11/02/18
HCWC
11/02/18
NO CHANGE
HCWC
Buy
BioDelivery prescriptions for Belbuca accelerating, says H.C. Wainwright
H.C. Wainwright analyst Oren Livnat said the latest IQVIA data, through the week ending October 26, for prescription volume trends for Belbuca "easily hit a new all-time high," noting that prescriptions for BioDelivery Sciences' film for chronic pain are accelerating upward. He added that current trends come ahead of additional PBM formulary wins. The analyst, who said that he is "comfortable" with his "Street-high" $80M Belbuca sales estimate in 2019, keeps a Buy rating on BioDelivery Sciences shares.
10/08/18
HCWC
10/08/18
NO CHANGE
Target $5
HCWC
Buy
BioDelivery Sciences price target raised to $5 from $4 at H.C. Wainwright
H.C. Wainwright analyst Oren Livnat raised his price target for BioDelivery Sciences to $5 citing the company's "upbeat" analyst day. All indications are that with continued commercial and managed care execution, Belbuca will continue to gain market share, Livnat tells investors in a research note. He sees management's projected $200M potential as achievable and keeps a Buy rating on the shares.
12/13/18
CANT
12/13/18
NO CHANGE
Target $5
CANT
Overweight
BioDelivery Sciences exceeding execution goals, says Cantor Fitzgerald
After a day of meetings with management, Cantor Fitzgerald analyst Brandon Folkes says that based on Symphony script data so far in 2018, the company is exceeding its execution goals as well as his expectations. The sentiment at the meetings "was positive with a common theme of delving into whether the company has the foundation to continue to execute in 2019 as it has in 2018," Folkes tells investors in a research note. The analyst has increased conviction that "solid execution" in 2019 and beyond is likely to continue, which he believes should drive upward earnings revisions and further upside in BioDelivery shares. Folkes reiterates an Overweight rating on the name with a $5 price target.
07/06/18
HCWC
07/06/18
NO CHANGE
HCWC
Buy
BioDelivery's Belbuca prescription trends accelerating, says H.C. Wainwright
H.C. Wainwright analyst Oren Livnat said weekly prescription data through June 29 shows Belbuca trends are accelerating and prescription volumes are making new highs, with Q2 Belbuca sales trending to approximately $10.4M, topping the $9.8M consensus forecast. Belbuca's implied annualized run-rate of nearly $48M at the half-way point of the year compares favorably to the 2018 consensus of about $41M, added Livnat, who keeps a Buy rating on BioDelivery Sciences shares.
CTSO CytoSorbents
$8.25

-0.305 (-3.57%)

GNCA Genocea
$0.57

0.0337 (6.25%)

03/08/18
HCWC
03/08/18
INITIATION
Target $5
HCWC
Buy
Genocea initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis started Genocea Biosciences with a Buy rating and $5 price target. The analyst believes the company's approach to vaccines could add to the standard of care for leading tumor indications.
03/08/18
03/08/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tyler Technologies (TYL) initiated with a Neutral at DA Davidson. 2. Interpace Diagnostics (IDXG) initiated with a Buy at H.C. Wainwright. 3. Crispr Therapeutics (CRSP) initiated with an Outperform at JMP Securities. 4. Quanta Capital Hldgs (QNTA) initiated with an Outperform at Northland. 5. Genocea (GNCA) initiated with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/12/18
CANT
03/12/18
NO CHANGE
Target $5
CANT
Overweight
Genocea shares could be weak on CFO resignation, says Cantor Fitzgerald
Cantor Fitzgerald analyst Mara Goldstein says shares of Genocea Biosciences could experience some weakness on the news of the departure of CFO Jonathan Pool. While the news is disappointing, the departure is amicable, and Poole will assist with the transition during the rest of his tenure, Goldstein tells investors in a research note. She believes Genocea has sufficient capital to advance GEN-009 through early trials. The analyst maintains an Overweight rating on the stock with a $5 price target.
03/06/18
03/06/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Becton Dickinson (BDX) initiated with a Market Perform at BMO Capital. 2. Cardlytics (CDLX) initiated with a Buy at SunTrust, an Overweight at JPMorgan and KeyBanc, a Neutral at BofA/Merrill, and an Outperform at Wells Fargo. 3. iRhythm (IRTC) initiated with an Outperform at BMO Capital. 4. Genocea (GNCA) initiated with an Overweight at Cantor Fitzgerald. 5. Domino's Pizza (DPZ) initiated with an Outperform at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
MDWD MediWound
$4.29

-0.01 (-0.23%)

09/25/18
WELS
09/25/18
NO CHANGE
Target $11
WELS
Outperform
MediWound BARDA contract 'highly value-creating,' says Wells Fargo
Wells Fargo analyst David Maris estimates MediWound's new BARDA contract to develop NexoBrid for the treatment of Sulfur Mustard injuries should be worth approximately $1 per share. The analyst views the deal as an "endorsement of the promise" of NexoBrid and the potential for longer-term government contracts if approved. He currently does not model NexoBrid government sales but believes the size of the mass casualty preparedness market could rival the burn market. Overall, the contract from the U.S. Biomedical Advanced Research and Development Authority is a "highly value-creating deal," Maris tells investors in a research note. He keeps an Outperform rating on MediWound with an $11 price target.
08/08/18
WELS
08/08/18
NO CHANGE
Target $11
WELS
Outperform
MediWound could be sold for 'substantially higher price,' says Wells Fargo
Wells Fargo analyst David Maris noted that MediWound's Chairman said on the company's earnings call that while the board previously thought it would have more clarity by its Q2 report on its previously disclosed consideration of a potential strategic transaction, the company is taking a "comprehensive and measured approach" as it is still in talks with several parties. If MediWound is able to conclude a strategic combination, it would be for "a substantially higher price" and one that contemplates cash flows beyond Maris' current assumptions, he stated. Maris keeps an Outperform rating and $11 price target on MediWound shares.
05/29/18
WELS
05/29/18
NO CHANGE
WELS
Outperform
MediWound may now be more attractive to potential buyers, says Wells Fargo
Wells Fargo analyst David Maris believes MediWound could be more attractive to a broader range of potential buyers, including those in the medical countermeasure space, after the FDA cleared the development pathway for NexoBrid for the debridement of skin injuries inflicted by chemical warfare agent sulfur mustard. The FDA also agreed to allow the development of NexoBrid in sulfur mustard wounds to rely on the chemistry, manufacturing and control data from NexoBrid's previous and ongoing development in burns, Maris points out. He views this as good news for MediWound and keeps an Outperform rating on the shares.
PFNX Pfenex
$4.24

0.21 (5.21%)

ONS Oncobiologics
$0.00

(0.00%)

01/29/18
01/29/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Starbucks (SBUX) downgraded to Market Perform from Outperform at Bernstein with analyst Sara Senatore saying she believes the business mix is clearly shifting toward China just not fast enough to offset the U.S. The analyst also lowered her price target for $64 from $67. 2. CBS (CBS) downgraded to Market Perform from Outperform at Wells Fargo with analyst Marci Ryvicker saying she does not like the company's potential merger with Viacom (VIAB). 3. Oncobiologics (ONS) downgraded to Equal Weight from Overweight at Barclays with analyst Douglas Tsao saying he sees a lack of clarity in the go forward business. 4. Alliance Data (ADS) downgraded to Market Perform from Outperform at Cowen with analyst George Mihalos saying believes the shares are reaching fair value and that many of its catalysts from 2018 will not repeat over the intermediate term. 5. Fortis (FTS) downgraded to Underperform from Sector Perform at National Bank. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/29/18
LEHM
01/29/18
DOWNGRADE
Target $1.5
LEHM
Equal Weight
Oncobiologics downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Douglas Tsao downgraded Oncobiologics to Equal Weight and cut his price target for the shares to $1.50 from $11. The analyst sees a lack of clarity in the go forward business. His new price target reflects removal of U.S. Humira and Avastin biosimilar opportunities and the addition of contract manufacturing and emerging market revenues.
NSPR InspireMD
$0.18

0.012 (7.14%)

PTN Palatin
$0.72

-0.0358 (-4.72%)

06/14/18
HCWC
06/14/18
NO CHANGE
HCWC
Buy
Palatin weakness 'undeserved' following Addyi relaunch, says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis attributes recent weakness in shares of Palatin (PTN) to the relaunch of Addyi by Sprout, and its first-to-market status, following reacquisition of the drug from Valeant (VRX). However, he sees the weakness as undeserved, as he continues to believe that Addyi is an inferior drug with a "sketchy history," Pantginis tells investors. Addyi's "one singular advantage," education and visibility for hypoactive sexual desire disorder, should help the market for Palatin's bremelanotide, which has a "potentially market leading profile," said the analyst, who keeps a Buy rating on Palatin shares.
06/27/18
LTCO
06/27/18
INITIATION
Target $3
LTCO
Buy
Palatin initiated with a Buy at Ladenburg
Ladenburg analyst Michael Higgins initiated Palatin with a Buy rating and $3 price target.
04/06/18
HCWC
04/06/18
INITIATION
Target $5
HCWC
Buy
Palatin initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis started Palatin Technologies with a Buy rating and $5 price target. The analyst views the company's lead asset bremelanotide, which is in development for hypoactive sexual desire disorder in women, as "significantly derisked." He believes the drug's "checked boxes" and projected catalysts are not reflected in the current share price.
PRTA Prothena
$11.41

0.04 (0.35%)

04/24/18
BTIG
04/24/18
DOWNGRADE
BTIG
Neutral
Prothena downgraded to Neutral from Buy at BTIG
BTIG analyst Robert Hazlett downgraded Prothena to Neutral from Buy after the PRONTO study read out negatively, which led directly to the discontinuation of the entire NEOD001 program. Despite noting that the company has programs "that appear quite promising," Hazlett prefers to move to the sidelines with important catalysts now farther out, with a readout for its 002 program in Parkinson's due in 2020.
04/24/18
04/24/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Alcoa (AA) downgraded to Neutral from Buy at Citi with analyst Alexander Hacking saying the stock is up 60% year-over-year. 2. Dynagas LNG (DLNG) downgraded to Underperform from Market Perform at Wells Fargo with analyst Michael Webber saying another distribution cut is possible given expensive dropdowns from the company's private sponsor. 3. Skyworks (SWKS) downgraded to Neutral from Buy at Mizuho with analyst Vijay Rakesh saying the effects of a maturing handset cycle could start to impact the RF suppliers. 4. Prothena (PRTA) downgraded to Neutral from Buy at BTIG and to Perform from Outperform at Oppenheimer. 5. Donegal Group (DGICA) downgraded to Neutral from Outperform at Boenning & Scattergood. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/15/18
CANT
06/15/18
NO CHANGE
Target $18
CANT
Overweight
Prothena price target raised to $18 from $14 at Cantor Fitzgerald
Cantor Fitzgerald analyst William Tanner raised his price target for Prothena to $18 citing his analysis of the potential value of the company's drug discovery platform and management's recently announced restructuring plan. The analyst reiterates a Overweight rating on the shares.
05/21/18
LEHM
05/21/18
DOWNGRADE
Target $12
LEHM
Underweight
Prothena downgraded to Underweight from Equal Weight at Barclays
Barclays analyst Geoffrey Meacham downgraded Prothena to Underweight and cut his price target for the shares to $12 from $14. The analyst sees limited value creating pipeline events in the near-term after the company discontinued development of NEOD001, an investigational antibody that was being evaluated for the treatment of AL amyloidosis. He believes it remains too early to assign much value to PRX002 in Parkinson's or PRX004 in ATTR amyloidosis.
DRRX Durect
$0.56

0.0035 (0.63%)

03/06/18
HCWC
03/06/18
UPGRADE
Target $3.5
HCWC
Buy
Durect upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright analyst Ed Arce upgraded Durect (DRRX) to Buy with a $3.50 price target. Investor sentiment has begun to shift to a positive bias, based on the broad preclinical and Phase 1 data set, and large commercial opportunity, of DUR-928, Acre tells investors in a research note. In addition to two Phase 2 data catalysts this year, investors can look to two near-term potential FDA approvals on partnered assets, Indivior's RBP-7000 and Pain Therapeutics' (PTIE) Remoxy, the analyst adds.
TCON TRACON Pharmaceuticals
$0.82

-0.0005 (-0.06%)

12/26/18
BTIG
12/26/18
NO CHANGE
Target $9
BTIG
Buy
TRACON Pharmaceuticals price target lowered to $9 from $13 at BTIG
BTIG analyst Robert Hazlett lowered his price target on TRACON Pharma to $9 after the company's recent announcement that its Phase 2b TRAXAR trial of TRC105+Intyla in renal cell carcinoma, or RCC, did not meet the primary endpoint of improving progression free survival. The analyst states that the findings have led him to remove the RCC estimates from his model, leading to a lower price target. Hazlett is keeping his Buy rating on Tracon Pharma as he continues to have "material expectations for 105 in angiosarcoma, as well as its opportunities in wet AMD with DE-122 and prostate cancer with TRC253.
05/10/18
NEED
05/10/18
NO CHANGE
Target $8
NEED
Buy
TRACON Pharmaceuticals price target lowered to $8 from $16 at Needham
Needham analyst Chad Messer lowered his price target on TRACON Pharmaceuticals to $8 after its Q1 earnings miss as well as to reflect the dilution from its recent equity raise. Longer term, Messer keeps his Buy rating, noting Tracon's value drivers this year remain the "interim analysis of the pivotal TAPPAS study of TRC105 in angiosarcoma and randomized Phase II TRAXAR data testing TRC105+Inlyta in renal cell carcinoma".
VBLT VBL Therapeutics
$1.08

-0.02 (-1.82%)

03/08/18
CHDN
03/08/18
DOWNGRADE
Target $3
CHDN
Neutral
VBL Therapeutics downgraded to Neutral from Buy at Chardan
Chardan analyst Gbola Amusa downgraded VBL Therapeutics to Neutral and cut his price target for the shares to $3 from $25. The analyst believes this morning's failed trial offers little reason for optimism.
03/08/18
03/08/18
DOWNGRADE

Market Perform
VBL Therapeutics downgraded to Market Perform at JMP Securities
As previously reported, JMP Securities analyst Michael King downgraded VBL Therapeutics to Market Perform from Outperform after the company announced that the Phase III GLOBE study of VB-111 in rGBM did not meet its primary endpoint. At this time, the analyst believes the market fairly values the shares.
03/08/18
JMPS
03/08/18
DOWNGRADE
JMPS
Market Perform
VBL Therapeutics downgraded to Market Perform from Outperform at JMP Securities
10/15/18
HCWC
10/15/18
UPGRADE
Target $3
HCWC
Buy
VBL Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth upgraded VBL Therapeutics to Buy with an unchanged price target of $3. The "unwarranted" valuation decline and clinical readout in 2019 bring "new opportunity," Ramakanth tells investors in a research note. The stock has fallen 46% since March 3 despite no negative news from the company, the analyst says. He believes VBL's "promising" pipeline developments over the last six months, the weakness in the stock price, and the major clinical readout expected in 2019 has "significantly increased" the company's value proposition.
VELO VeloCom Inc.
$0.00

(0.00%)

ZGNX Zogenix
$44.47

1.24 (2.87%)

12/03/18
STFL
12/03/18
NO CHANGE
STFL
Buy
Zogenix cardiac safety data for ZX008 look 'pristine,' says Stifel
Stifel analyst Paul Matteis said the long-term cardiac safety data for ZX008 presented by Zogenix at the American Epilepsy Society from the ongoing 232 patient open-label extension study "continue to look pristine" and the long-term efficacy data show an impressive retention rate and sustained seizure reductions. The analyst, who adds that the new data are suggestive of drug benefit beyond just seizure reductions, reiterates his Buy rating on Zogenix following the AES meeting.
11/13/18
LEER
11/13/18
INITIATION
Target $60
LEER
Outperform
Zogenix initiated with an Outperform at Leerink
Leerink analyst Marc Goodman started Zogenix with an Outperform and $60 price target as he initiates Neuroscience space with a Positive View. The analyst believes the Neuroscience sector is experiencing a "renaissance" as multiple new agents and mechanisms are coming up the pipeline across major therapeutic areas, the number of clinical studies is growing nicely, and the FDA is friendly to innovation in this space, companies are getting smarter about speed-to-market strategies and selecting niche sub-populations to focus on for initial product approvals, payer pushback on usage is much lower than in other categories, and physicians are enthusiastic about new agents. Regarding Zogenix, Goodman likes the epilepsy market for novel drugs because of physician enthusiasm for new agents based on a high unmet need and relatively low payer pushback. Further, he believes Fintepla's strong clinical profile should drive sales of about $1B in 2029.
12/05/18
PIPR
12/05/18
NO CHANGE
Target $72
PIPR
Overweight
Piper likes Zogenix into 2019 on potential Dravet Syndrome approval
After catching up with Zogenix management, Piper Jaffray analyst Danielle Brill says she believes Fintepla's efficacy is superior to other available agents for Dravet Syndrome. The analyst continues to like the shares into 2019 and reiterates an Overweight rating on the name with a $72 price target. Brill expects a positive FDA panel/approval in Q3 of 2019 to drive shares higher next year. Further, she sees additional upside if labeling is favorably differentiated from competitor drugs.
11/12/18
LEER
11/12/18
INITIATION
Target $60
LEER
Outperform
Zogenix initiated with an Outperform at Leerink
Leerink Partners analyst Marc Goodman started Zogenix with an Outperform rating and $60 price target.
FOMX Foamix
$4.02

-0.04 (-0.99%)

11/07/18
COWN
11/07/18
NO CHANGE
Target $30
COWN
Outperform
Foamix sale now more likely after Phase 3 trial successes, says Cowen
Cowen analyst Ken Cacciatore said that after Foamix Pharmaceuticals announced a successful Phase 3 program evaluating FMX103 in the treatment of moderate-to-severe papulopustular rosacea on the heels of the Phase 3 success in acne, he believes strategic interest will now likely accelerate. He notes that management indicated that they don't think they need additional capital to execute on their filing strategy or initial launch, which is "the type of commentary" he interprets as potentially signaling a willingness to entertain a potential business development deal or outright sale. Given the value of recent deals in the space, Cacciatore added that he believes Foamix shares are "meaningfully undervalued." The analyst keeps an Outperform rating and $30 price target on Foamix.
12/04/18
HCWC
12/04/18
NO CHANGE
Target $12
HCWC
Buy
Foamix remains 'substantially undervalued,' says H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Foamix Pharmaceuticals to $12 from $11 citing the positive top-line results from two pivotal Phase 3 clinical trials of FMX103 for the treatment of moderate-to-severe papulopustular rosacea. The analyst believes the high level of statistical significance underscores the degree of efficacy observed. He reiterates a Buy rating on Foamix and says the stock remains "substantially undervalued."
12/12/18
BOFA
12/12/18
INITIATION
Target $11
BOFA
Buy
Foamix initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Jason Gerberry initiated Foamix with a Buy and $11 price target citing de-risked dermatology assets. Gerberry said Foamix offers two late-stage drugs with efficacy that are competitive to existing therapies but offer a topical alternative to widely used oral minocycline, with less safety baggage as a systemically absorbed drug. The analyst thinks FMX-101 and -103 will take market share and build recognition in the "experience-driven derm space."
12/12/18
12/12/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Foamix (FOMX) initiated with a Buy at BofA/Merrill. 2. Jazz Pharmaceuticals (JAZZ) initiated with an Outperform at Oppenheimer while GW Pharmaceuticals (GWPH) was initiated with a Perform. 3. Six Flags (SIX) initiated with a Buy at Berenberg. 4. iQIYI (IQ) initiated with a Hold at HSBC. 5. Intercept (ICPT), Viking Therapeutics (VKTX), and Galmed (GLMD) were initiated with a Buy at B. Riley FBR, while Madrigal Pharmaceuticals (MDGL) initiated with a Neutral. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
LIFE aTyr Pharma
$0.54

-0.0209 (-3.72%)

10/08/18
PIPR
10/08/18
NO CHANGE
PIPR
aTyr Pharma price target lowered to $1.80 from $3 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff remained Overweight on aTyr Pharma, but lowered his price target on shares to $1.80 from $3, by "valuing ATYR-1923 in pulmonary sarcoidosis and rolling forward [the firm's] discount period to year end 2019." Tenthoff noted that aTyr plans to begin a Phase Ib/IIa placebo-controlled study for ATYR1923 to treat pulmonary sarcoidosis with preliminary data by year end 2019.
05/15/18
05/15/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Ford (F) downgraded to Neutral from Overweight at Piper Jaffray with analyst Alexander Potter saying that while stock's valuation still appears low, relative to other stocks he covers, he's less convinced that Ford "can find compelling revenue drivers to offset secular threats." 2. aTyr Pharma (LIFE) downgraded to Sell from Neutral at Citi with analyst Joel Beatty saying a lack of clinical data and early stage of understanding for lead agent ATYR1923 create a low probability of success. 3. ClearOne (CLRO) downgraded to Neutral from Buy at B. Riley FBR. 4. Travelport (TVPT) downgraded to Neutral on valuation at BofA/Merrill with analyst John King citing relative valuation. 5. W&T Offshore (WTI) downgraded to Sell from Hold at KLR Group with analyst Gail Nicholson citing the stock's out-performance of the SPDR Oil Exploration and Production Fund (XOP) by about 54% over the last month. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/15/18
SBSH
05/15/18
DOWNGRADE
Target $1
SBSH
Sell
aTyr Pharma downgraded to Sell with $1 target at Citi
Citi analyst Joel Beatty last night downgraded aTyr Pharma to Sell from Neutral and cut his price target to $1 from $4. A lack of clinical data and early stage of understanding for lead agent ATYR1923 create a low probability of success, Beatty told investors in a research note. aTyr yesterday announced the end of its preclinical ORCA program due to lack of sufficient efficacy as well as a 30% workforce reduction.
08/16/18
SBSH
08/16/18
UPGRADE
SBSH
Neutral
aTyr Pharma upgraded to Neutral from Sell at Citi
ENTX Entera Bio
$3.12

(0.00%)

08/03/18
MAXM
08/03/18
INITIATION
MAXM
Buy
Entera Bio initiated with a Buy at Maxim
Maxim analyst Jason McCarthy initiated Entera Bio with a Buy rating and $12 price target.
08/03/18
08/03/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with a Hold at Canaccord. 2. Universal Forest (UFPI) initiated with a Buy at Seaport Global. 3. Zafgen (ZFGN) initiated with an Outperform at Wedbush. 4. Entera Bio (ENTX) initiated with a Buy at Maxim. 5. Huya initiated with a Neutral at Goldman Sachs. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
CBIO Catalyst Biosciences
$9.48

-0.51 (-5.11%)

01/03/19
OPCO
01/03/19
INITIATION
Target $24
OPCO
Outperform
Catalyst Biosciences initiated with Outperform at Oppenheimer
Oppenheimer analyst Kevin DeGeeter initiated Catalyst Biosciences with an Outperform rating and a price target of $24. The analyst notes that the company offers a "unique approach" in hemophilia treatment, asking key questions about the "best method to transition inhibitor patients from products designed to treat bleeding to prophylaxis for preventing bleeds" and the optimal treatment of "pediatric hemophilia B patients that are not candidates for subcutaneous non-factor replacement therapies or gene therapy". DeGeeter contends that investors are under-appreciating Catalyst Biosciences' Factor VIIa program and anticipates the investment story for the stock to solidify this year.
06/21/18
06/21/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Nike (NKE) downgraded to Neutral from Buy at UBS with analyst Jay Sole saying Nike's "comeback after two relatively down years continues." 2. Infinera (INFN) downgraded to Neutral from Buy at Goldman Sachs with analyst Rod Hall assumed coverage from Doug Clark and downgrading the stock to Neutral from Buy while saying the company's success is dependent on the new products, while its "key higher TAM products are yet to fully hit the market." 3. AMC Networks (AMCX) downgraded to Underperform from Market Perform at Bernstein with analyst Todd Juenger saying he thinks it is unlikely the company will be acquired at a premium. 4. Catalyst Biosciences (CBIO) downgraded to Neutral from Buy at B. Riley FBR. 5. Noble Corp. (NE) downgraded to Hold from Buy at Jefferies with analyst Eduardo Royes saying the stock is up 18% year-to-date versus its four major peers rising only 2%. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/21/18
RILY
06/21/18
DOWNGRADE
Target $12.5
RILY
Neutral
Catalyst Biosciences downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst George Zavoico downgraded Catalyst Biosciences to Neutral and cut his price target for the shares to $12.50 from $44.
01/04/19
01/04/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aveo Pharmaceuticals (AVEO) initiated with an Outperform at Baird. 2. Catalyst Biosciences (CBIO) initiated with Outperform at Oppenheimer. 3. Infinity Pharmaceuticals (INFI) initiated with a Buy at B. Riley FBR. 4. Rockwell Automation (ROK) resumed with a Hold at Deutsche Bank. 5. Dell Technologies (DELL) initiated with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
INSP Inspire Medical
$46.24

0.65 (1.43%)

10/29/18
LEER
10/29/18
INITIATION
Target $57
LEER
Outperform
Inspire Medical initiated with an Outperform at Leerink
Leerink analyst Richard Newitter started Inspire Medical with an Outperform rating and $57 price target. The analyst sees it as a sustainable ultra high-growth/gross margin small-cap as the company drives higher utilization of its first and only FDA-approved neurostimulation device for obstructive sleep apnea, where current therapies have drawbacks and Inspire Medical's unique solution can offer patient benefits over them.
05/29/18
BOFA
05/29/18
INITIATION
Target $36
BOFA
Neutral
Inspire Medical initiated with a Neutral at BofA/Merrill
BofA/Merrill analyst Bob Hopkins initiated Inspire Medical with a Neutral and $36 price target due to valuation.
11/28/18
BREN
11/28/18
INITIATION
Target $31
BREN
Sell
Inspire Medical initiated with a Sell at Berenberg
Berenberg initiated Inspire Medical with a Sell and $31 price target.
05/29/18
STFL
05/29/18
INITIATION
Target $42
STFL
Buy
Inspire Medical initiated with a Buy at Stifel
Stifel analyst Jonathan Block started Inspire Medical Systems with a Buy rating and $42 price target, stating that his diligence with ENTs and Sleep Specialists identifies a significant opportunity for the company's Upper Airway Stimulation procedure to gain market share from more invasive surgical procedures. Block also believes the company's clinical data is likely robust enough to eventually win over commercial payors and sets a high hurdle for future competitors, he tells investors.
OCX OncoCyte
$1.88

0.24 (14.63%)

07/11/18
07/11/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Alphabet (GOOGL, GOOG), Facebook (FB), and Spotify (SPOT) were initiated with a Buy at Nomura Instinet while Twitter (TWTR) was initiated with a Reduce. 2. AMC Entertainment (AMC) and Cinemark (CNK) were initiated with an Outperform at Imperial Capital. 3. Keurig Dr Pepper (KDP) initiated with a Hold at Stifel. 4. Myers Industries (MYE) initiated with a Neutral at Baird and JPMorgan. 5. TPG Pace Energy (TPGE) initiated with an Outperform at Northland. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/11/18
BNCH
07/11/18
INITIATION
Target $7
BNCH
Buy
OncoCyte assumed with a Buy from a Speculative Buy at Benchmark
Benchmark analyst Bruce Jackson assumed coverage of OncoCyte with a Buy rating and $7 price target, stating that he sees a "clear pathway to commercial availability" for its blood-based lung cancer test, which he believes can prevent the need for risky and expensive lung tissue biopsy procedures. The stock was previously covered by Raymond Myers, who'd had a Speculative Buy rating on OncoCyte.
12/19/18
LSCM
12/19/18
INITIATION
Target $4
LSCM
Buy
OncoCyte assumed with a Buy at Lake Street
Lake Street analyst Thomas Flaten assumed coverage of OncoCyte with a Buy rating and $4 price target. The company's DetermaVu is a non-invasive confirmatory diagnostic with the potential to improve lung cancer diagnosis and care, while reducing costs to the system, Flaten tells investors in a research note.
09/10/18
JANY
09/10/18
NO CHANGE
Target $4
JANY
Buy
OncoCyte price target raised to $4 from $2 at Janney Montgomery Scott

TODAY'S FREE FLY STORIES

CLR

Continental Resources

$46.94

1.8 (3.99%)

17:14
02/18/19
02/18
17:14
02/18/19
17:14
Earnings
Continental Resources reports Q4 adjusted 54c, consensus 62c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 04

    Mar

SPN

Superior Energy

$4.43

0.165 (3.87%)

16:53
02/18/19
02/18
16:53
02/18/19
16:53
Earnings
Superior Energy reports Q4 EPS ($4.85), may not compare consensus (0.28c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

MSG

Madison Square Garden

$291.37

0.85 (0.29%)

16:46
02/18/19
02/18
16:46
02/18/19
16:46
Periodicals
MSG denies Knicks sale talks after Bill Simmons claims otherwise »

Madison Square Garden…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$3.37

0.2 (6.31%)

16:45
02/18/19
02/18
16:45
02/18/19
16:45
Hot Stocks
Windstream postpones release of Q4, FY18 financial results »

Windstream announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

UFPI

Universal Forest

$32.22

0.36 (1.13%)

16:43
02/18/19
02/18
16:43
02/18/19
16:43
Hot Stocks
Universal Forest signs agreement to acquire Wolverine Wood Products »

Universal Forest Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

SCI

Service Corp.

$45.96

0.56 (1.23%)

16:36
02/18/19
02/18
16:36
02/18/19
16:36
Earnings
Breaking Earnings news story on Service Corp. »

Service Corp. sees FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

SCI

Service Corp.

$45.96

0.56 (1.23%)

16:34
02/18/19
02/18
16:34
02/18/19
16:34
Earnings
Service Corp. reports Q4 adjusted EPS 54c, consensus 56c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

APY

Apergy

$36.84

0.92 (2.56%)

16:27
02/18/19
02/18
16:27
02/18/19
16:27
Earnings
Apergy reports Q4 adjusted EPS 36c, consensus 33c »

Reports Q4 revenue of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

NAVI

Navient

$11.75

0.12 (1.03%)

16:20
02/18/19
02/18
16:20
02/18/19
16:20
Hot Stocks
Navient rejects highly conditional unsolicited 'expression of interest' »

Navient announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLCA

U.S. Silica

$14.41

-0.005 (-0.03%)

16:15
02/18/19
02/18
16:15
02/18/19
16:15
Hot Stocks
24 SandBox Logistics patent claims invalidated »

Proppant Express…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 28

    May

JBHT

J.B. Hunt

$113.78

1.66 (1.48%)

16:12
02/18/19
02/18
16:12
02/18/19
16:12
Hot Stocks
J.B. Hunt completes acquisition of Cory 1st Choice Home Delivery »

J.B. Hunt announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 06

    Mar

CAT

Caterpillar

$136.21

3.575 (2.70%)

16:10
02/18/19
02/18
16:10
02/18/19
16:10
Hot Stocks
Caterpillar announces several officer moves »

Caterpillar announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

CUB

Cubic

$60.35

2.995 (5.22%)

16:07
02/18/19
02/18
16:07
02/18/19
16:07
Hot Stocks
Cubic announces semiannual dividend of 13.5c per share »

Cubic announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 19

    Feb

  • 20

    Feb

  • 20

    Feb

  • 21

    Feb

HMC

Honda

$27.35

0.04 (0.15%)

13:11
02/18/19
02/18
13:11
02/18/19
13:11
Periodicals
Honda plan to close U.K. plant not due to Brexit, Reuters reports »

Honda plans to shut its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMC

Honda

$27.35

0.04 (0.15%)

13:07
02/18/19
02/18
13:07
02/18/19
13:07
Periodicals
Honda to close U.K. car plant in 2022, Reuters reports »

Honda is set to announce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LUNMF

Lundin Mining

$0.00

(0.00%)

13:04
02/18/19
02/18
13:04
02/18/19
13:04
Downgrade
Lundin Mining rating change at Goldman Sachs »

Lundin Mining downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVR

Chicago Rivet & Machine

$28.36

0.56 (2.01%)

12:38
02/18/19
02/18
12:38
02/18/19
12:38
Hot Stocks
Chicago Rivet & Machine announces increase in quarterly cash dividend to 22c »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGX

Quest Diagnostics

$87.77

2.27 (2.66%)

, XRX

Xerox

$30.46

0.63 (2.11%)

12:36
02/18/19
02/18
12:36
02/18/19
12:36
Hot Stocks
Quest Diagnostics names Gabrielle Wolfson senior VP, CIO »

Quest Diagnostics (DGX)…

DGX

Quest Diagnostics

$87.77

2.27 (2.66%)

XRX

Xerox

$30.46

0.63 (2.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRDX

Surmodics

$56.79

3.09 (5.75%)

12:29
02/18/19
02/18
12:29
02/18/19
12:29
Hot Stocks
Surmodics announces appointment of Timothy Arens as CFO »

Surmodics announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 06

    Mar

  • 07

    Mar

CUB

Cubic

$60.35

2.995 (5.22%)

, IBM

IBM

$138.05

1.55 (1.14%)

12:28
02/18/19
02/18
12:28
02/18/19
12:28
Hot Stocks
Cubic names IBM, Microsoft executive Kevin Eagan as Senior VP, Chief Digital »

Cubic (CUB) announced the…

CUB

Cubic

$60.35

2.995 (5.22%)

IBM

IBM

$138.05

1.55 (1.14%)

MSFT

Microsoft

$108.19

1.35 (1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 19

    Feb

  • 20

    Feb

  • 20

    Feb

  • 21

    Feb

  • 25

    Feb

  • 03

    Mar

  • 04

    Mar

  • 06

    Mar

  • 07

    Mar

  • 18

    Mar

CGUSY

Casino Guichard Perrachon

$0.00

(0.00%)

11:50
02/18/19
02/18
11:50
02/18/19
11:50
Downgrade
Casino Guichard Perrachon rating change at Deutsche Bank »

Casino Guichard…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPYYY

Centrica

$0.00

(0.00%)

11:46
02/18/19
02/18
11:46
02/18/19
11:46
Downgrade
Centrica rating change at Berenberg »

Centrica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
02/18/19
02/18
11:15
02/18/19
11:15
General news
FX Summary: AUD-JPY has been the biggest mover »

FX Summary: AUD-JPY has…

MSM

MSC Industrial

$86.24

0.81 (0.95%)

11:07
02/18/19
02/18
11:07
02/18/19
11:07
Hot Stocks
MSC Industrial reports patent issued for cost-savings documentation system »

As previously reported on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

08:35
02/18/19
02/18
08:35
02/18/19
08:35
General news
Oil Action: Front-month WTI crude futures are up 1.0% »

Oil Action: Front-month…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.